drugset / Trial / NCT03840343
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The Researchers will assess the safety, tolerability, dosing effect, and early signals of efficacy of intra-arterially delivered autologous (from self) adipose (fat) tissue-derived mesenchymal stem/stromal cells (MSC) in patients with progressive diabetic kidney disease (DKD).
Timeline
- Start
- 2019-10-23
- Primary completion
- 2020-08-04
- Completion
- 2020-08-04
Outcome
Outcome not reported
Stopped: “Principal Investigator relocation”
Publications
- Background Patel HA, Wang J, Zinn CJ, Learmonth M, Lerman LO, Wolfram J, Hickson LJ. Fortifying the Diabetic Kidney Disease Treatment Armamentarium: Multitarget Senotherapeutic and Regenerative Strategies. J Am Soc Nephrol. 2025 May 7;36(8):1655-1658. doi: 10.1681/ASN.0000000754. No abstract available.
- Results Alatta LS, Elhusseiny KM, Dietz AB, Herrmann SM, Lorenz EC, Lawson DK, Bendel EC, Reisenauer CJ, Misra S, Vaughan LE, Lerman LO, Hickson LJ. Intraarterial Autologous Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease. Kidney Int Rep. 2025 Aug 6;10(10):3656-3660. doi: 10.1016/j.ekir.2025.07.042. eCollection 2025 Oct. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous adipose-derived mesenchymal stem/stromal cells (MSC) | Cell therapy | 250000 cells/kg | Other |
| Subject | Autologous adipose-derived mesenchymal stem/stromal cells (MSC) | Cell therapy | 500000 cells/kg | Other |